Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Booster Dose (India)

This article was originally published in PharmAsia News

Executive Summary

Drug research and development is on the brink of being revolutionized by a new data-mining process known as chemoinformatics. A number of Indian pharmaceutical companies including Dr. Reddy's Laboratories, Wockhardt, Sun Pharma, Nicholas Piramal, and Ranbaxy are already beginning to take advantage of this technique. In chemoinformatics, researchers use computer software to create and search lists of thousands of chemical compounds. Scientists can then identify molecular combinations that are most promising for further development into new drugs. This technique can also help eliminate molecules with possibly toxic properties. By speeding up the chemical selection process, Indian drug manufacturers hope to gain the advantage over stiff international and generic competition. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel